What is the relationship between hyperamylasemia and the use of a GLP-1 (Glucagon-like peptide-1) agonist?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Relationship between Hyperamylasemia and GLP-1 Agonist Use

  • Hyperamylasemia, or elevated amylase levels, has been observed in patients using GLP-1 receptor agonists, as reported in a study published in 2012 1.
  • The study found that 36% of patients treated with a GLP-1 agonist or a DPP-4 inhibitor had an increase in serum amylase or lipase levels, compared to 18% in the comparison group.
  • The increase in serum lipase levels was more pronounced than the increase in serum amylase levels in all groups, suggesting possible pancreatic inflammation 1.
  • Another study published in 2022 discussed the physiological functions of GLP-1 and its development as a pharmaceutical agent for the treatment of obesity and type 2 diabetes, but did not specifically address the relationship between GLP-1 agonist use and hyperamylasemia 2.
  • A 2015 review of GLP-1 receptor agonists provided practical information for primary care physicians on the use of these agents in patients with type 2 diabetes, but did not mention hyperamylasemia as a potential side effect 3.
  • A 2025 study mapping the effectiveness and risks of GLP-1 receptor agonists found an increased risk of drug-induced pancreatitis associated with GLP-1RA use, which may be related to hyperamylasemia 4.
  • A 2015 review of head-to-head clinical studies of GLP-1 receptor agonists found that all agents in the class were effective at reducing A1C, but did not specifically address the relationship between GLP-1 agonist use and hyperamylasemia 5.

Key Findings

  • GLP-1 receptor agonists may be associated with increased levels of serum amylase and lipase, suggesting possible pancreatic inflammation 1.
  • The relationship between GLP-1 agonist use and hyperamylasemia is not fully understood and requires further study 1, 4.

References

1
Research

Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2012

5
Research

GLP-1 receptor agonists: a review of head-to-head clinical studies.

Therapeutic advances in endocrinology and metabolism, 2015

Related Questions

What are the management options for bruising and impaired wound healing associated with Zepbound (glucagon-like peptide-1 receptor agonist) therapy?
Can I prescribe vitamin D (Cholecalciferol) 50,000 units to a patient on a GLP-1 (Glucagon-like peptide-1) receptor agonist?
Are GLP-1 (Glucagon-Like Peptide-1) receptor agonists a cure-all for every medical condition?
What are the benefits of Glucagon-like peptides (GLP) beyond their effects on diabetes, cardiovascular disease, and renal function, particularly in relation to psychiatric and pulmonary disorders?
What are the contraindications to starting Glucagon-like peptide-1 (GLP-1) receptor agonist therapy?
What causes hyperamylasemia?
What is Aldactone (Spironolactone)?
What is the significance of elevated amylase and GLP1 (Glucagon-Like Peptide-1) levels?
What is the dose of ibuprofen for a 6-year-old, 45-pound child?
Who to refer for a cervical herniated disc?
What is the next step after a positive Purified Protein Derivative (PPD) test?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question